Inventor · disambiguated record
Harry J. Leighton
Also filed as: LEIGHTON HARRY · LEIGHTON HARRY J · LEIGHTON HARRY JEFFERSON
23 granted patents·29 pending applications·462 citations·filing 1985–2025
96Inventor score
Files withMILESTONE PHARMACEUTICALS INC18BURROUGHS WELLCOME CO7LEIGHTON HARRY J5HYPNION INC4MAINE NATURAL HEALTH COMPANY INC4
Top patents by PatentIndex Score
52 records- 0197US4923892ATricyclic aromatic compoundsBURROUGHS WELLCOME CO·Filed 1989·Granted May 8, 1990·87 cites·12 claims
- 0295US5019583AN-phenyl-N-(4-piperidinyl)amides useful as analgesicsGLAXO INC·Filed 1989·Granted May 28, 1991·58 cites·47 claims
- 0395US4879296AXanthine derivativesBURROUGHS WELLCOME CO·Filed 1986·Granted Nov 7, 1989·86 cites·19 claims
- 0494US4871865ATricyclic aromatic compoundsBURROUGHS WELLCOME CO·Filed 1986·Granted Oct 3, 1989·97 cites·3 claims
- 0592US2024366552A1Short acting phenylalkylamine calcium channel blockers and uses thereofMILESTONE PHARMACEUTICALS INC·Filed 2024·Application pending·0 cites
- 0691US7355042B2Treatment of CNS disorders using CNS target modulatorsHYPNION INC·Filed 2004·Granted Apr 8, 2008·49 cites·1 claims
- 0790US10010523B2Short acting phenylalkylamine calcium channel blockers and uses thereofMILESTONE PHARMACEUTICALS INC·Filed 2017·Granted Jul 3, 2018·4 cites·1 claims
- 0890US2024115543A1Short acting phenylalkylamine calcium channel blockers and uses thereofMILESTONE PHARMACEUTICALS INC·Filed 2023·Application pending·0 cites
- 0988US2023255923A1Short acting phenylalkylamine calcium channel blockers and uses thereofMILESTONE PHARMACEUTICALS INC·Filed 2023·Application pending·0 cites
- 1086US10010522B2Short acting phenylalkylamine calcium channel blockers and uses thereofMILESTONE PHARMACEUTICALS INC·Filed 2017·Granted Jul 3, 2018·2 cites·1 claims
- 1185US10010524B2Short acting phenylalkylamine calcium channel blockers and uses thereofMILESTONE PHARMACEUTICALS INC·Filed 2017·Granted Jul 3, 2018·2 cites·4 claims
- 1284US9737503B2Short acting phenylalkylamine calcium channel blockers and uses thereofMILESTONE PHARMACEUTICALS INC·Filed 2016·Granted Aug 22, 2017·2 cites·4 claims
- 1384US9629920B2Methods and compositions for stable liquid drug formulationsLEIGHTON HARRY J·Filed 2010·Granted Apr 25, 2017·6 cites·24 claims
- 1484US9463179B2Short acting phenylalkylamine calcium channel blockers and uses thereofMILESTONE PHARMACEUTICALS INC·Filed 2015·Granted Oct 11, 2016·2 cites·12 claims
- 1582US9227918B2Short acting phenylalkylamine calcium channel blockers and uses thereofMILESTONE PHARMACEUTICALS INC·Filed 2014·Granted Jan 5, 2016·2 cites·7 claims
- 1682US4981857APurine DerivativesBURROUGHS WELLCOME CO·Filed 1989·Granted Jan 1, 1991·23 cites·4 claims
- 1782US2022142963A1Short acting phenylalkylamine calcium channel blockers and uses thereofMILESTONE PHARMACEUTICALS INC·Filed 2022·Application pending·0 cites
- 1882US2025195462A1Short acting phenylalkylamine calcium channel blockers and uses thereofMILESTONE PHARMACEUTICALS INC·Filed 2025·Application pending·0 cites
- 1981US2021315855A1Short acting phenylalkylamine calcium channel blockers and uses thereofMILESTONE PHARMACEUTICALS INC·Filed 2021·Application pending·0 cites
- 2080US11224585B2Compositions containing omega-3 oil and uses thereofMAINE NATURAL HEALTH COMPANY INC·Filed 2019·Granted Jan 18, 2022·1 cites·29 claims
- 2179US9415035B2Compositions containing omega-3 oil with an anti-inflammatory agent and uses thereofLEIGHTON HARRY J·Filed 2011·Granted Aug 16, 2016·2 cites·7 claims
- 2279US4705854APhenothiazine compoundsBURROUGHS WELLCOME CO·Filed 1985·Granted Nov 10, 1987·14 cites·2 claims
- 2379US2021059972A1Short acting phenylalkylamine calcium channel blockers and uses thereofMILESTONE PHARMACEUTICALS INC·Filed 2020·Application pending·0 cites
- 2478US5015647AMethod for treating viral infectionsBURROUGHS WELLCOME CO·Filed 1989·Granted May 14, 1991·12 cites·6 claims
- 2575US2020230097A1Short acting phenylalkylamine calcium channel blockers and uses thereofMILESTONE PHARMACEUTICALS INC·Filed 2020·Application pending·0 cites
- 2674US2019380993A1Short acting phenylalkylamine calcium channel blockers and uses thereofMILESTONE PHARMACEUTICALS INC·Filed 2019·Application pending·0 cites
- 2772US9901638B2Composition and method for treating an autoimmune diseaseREDHILL BIOPHARMA LTD·Filed 2012·Granted Feb 27, 2018·2 cites·11 claims
- 2872US2019142781A1Short acting phenylalkylamine calcium channel blockers and uses thereofMILESTONE PHARMACEUTICALS INC·Filed 2019·Application pending·0 cites
- 2971US2018280339A1Short acting phenylalkylamine calcium channel blockers and uses thereofMILESTONE PHARMACEUTICALS INC·Filed 2018·Application pending·0 cites
- 3068US7317026B2CNS target modulatorsHYPNION INC·Filed 2003·Granted Jan 8, 2008·3 cites·14 claims
- 3168US2010190852A1Short acting phenylalkylamine calcium channel blockers and uses thereofMILESTONE PHARMACEUTICALS INC·Filed 2008·Application pending·0 cites
- 3266US7189757B2Treatment of sleep disorders using CNS target modulatorsHYPNION INC·Filed 2002·Granted Mar 13, 2007·3 cites·6 claims
- 3361US2017348272A1Compositions containing omega-3 oil and uses thereofMAINE NATURAL HEALTH COMPANY INC·Filed 2017·Application pending·0 cites
- 3461US2013203701A1Compositions containing omega-3 oil and uses thereofLEIGHTON HARRY J·Filed 2011·Application pending·0 cites
- 3555US2016095835A1Compositions containing omega-3 oil and uses thereofMAINE NATURAL HEALTH COMPANY INC·Filed 2015·Application pending·0 cites
- 3654US2015031704A1Methods and compositions for treating peripheral vascular diseaseEXODOS LIFE SCIENCES LTD PARTNERSHIP·Filed 2014·Application pending·0 cites
- 3752US2017224834A1Methods and compositions for stable liquid drug formulationsEXODOS LIFE SCIENCES LTD PARTNERSHIP·Filed 2017·Application pending·0 cites
- 3849US2006009465A1Treatment of sleep disorders using sleep target modulatorsEDGAR DALE·Filed 2003·Application pending·0 cites
- 3949US2003232839A1Treatment of sleeping disorders using CNS sleep target modulatorsHYPNION INC·Filed 2003·Application pending·0 cites
- 4049US2021161813A1Comestible compositions for promoting atp synthesisMAINE NATURAL HEALTH COMPANY INC·Filed 2021·Application pending·0 cites
- 4147US2005009730A1Treatment of cns disorders using cns target modulatorsFiled 2002·Application pending·0 cites
- 4247US2018036314A1Methods and compositions for treating peripheral vascular diseaseEXODOS LIFE SCIENCES LP·Filed 2017·Application pending·0 cites
- 4346US2013053393A1Methods and compositions for treating peripheral vascular diseaseFRANGAKIS CRIST J·Filed 2010·Application pending·0 cites
- 4445US2019105290A1Methods and compositions for treating and preventing trigeminal autonomic cephalgias, migraine, and vascular conditionsACHELIOS THERAPEUTICS INC·Filed 2018·Application pending·0 cites
- 4545US2007117978A1Cardiotonic compounds with inhibitory activity against beta-adrenergic receptors and phosphodiesteraseARTESIAN THERAPECUTICS INC·Filed 2003·Application pending·0 cites
- 4643US8501727B2Short acting benzothiazepine calcium channel blockers and uses thereofMAGUIRE MARTIN P·Filed 2009·Granted Aug 6, 2013·0 cites·28 claims
- 4743US2003130343A1Fat accumulation-modulating compoundsADIPOGENIX INC·Filed 2002·Application pending·0 cites
- 4840US2007066619A1Compounds having simultaneous ability to block L-type calcium channels and to inhibit phosphodiesterase type 3 activityARTESIAN THERAPEUTICS INC·Filed 2006·Application pending·0 cites
- 4939US2013109674A1Methods and compositions for treating and preventing trigeminal autonomic cephalgias, migraine, and vascular conditionsLEIGHTON HARRY J·Filed 2010·Application pending·0 cites
- 5038US7098211B2Compounds having simultaneous ability to block L-type calcium channels and to inhibit phosphodiesterase type 3 activityARTESIAN THERAPEUTICS INC·Filed 2003·Granted Aug 29, 2006·0 cites·14 claims
Showing the top 50 of 52 patent records by PatentIndex Score.
Join the waitlist — get patent alerts
Get an alert when Harry J. Leighton files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →